| Dr Farah Haq, MD | |
|
4 Smith Haven Mall Ste 202, Lake Grove, NY 11755-1219 | |
| (631) 444-6250 | |
| (631) 444-6665 |
| Full Name | Dr Farah Haq |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine |
| Experience | 13 Years |
| Location | 4 Smith Haven Mall Ste 202, Lake Grove, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609163872 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stony Brook Family And Preventive Medicine, University Faculty Practic | 7113816273 | 34 |
News Archive
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.
Immunotec Inc. announced today the enrollment of the first patient in the US Cancer trial of IMN 1207 being run at Beaumont Hospital's Community Clinical Oncology Program (CCOP) in Royal Oak, Michigan. The goal of the study is to determine the effect of IMN 1207, a cysteine-rich whey protein supplement, in preventing additional weight loss in patients with stage IV (advanced) non-small cell lung cancer.
To find the causes for cancer, biochemists and developmental biologists at the University of Innsbruck, Austria, retraced the function of an important human cancer gene 600 million years back in time. For the first time, they have identified the oncogene myc in a fresh water polyp and they have shown that this oncogene has similar biochemical functions in ancestral metazoan and in humans.
There is an ongoing debate about the role of psychological disorder symptoms as risk factors for temporomandibular joint (TMJ) pain. Previous studies have associated depression and TMJ pain but large scale studies have not been performed.
On November 10, 2004 investigators involved in a Phase IIa clinical trial of the novel biotoxin Tetrodotoxin (TTX) for the treatment of opioid withdrawal enrolled their first participants.
› Verified 5 days ago
| Entity Name | Stony Brook Family And Preventive Medicine, University Faculty Practic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982659470 PECOS PAC ID: 7113816273 Enrollment ID: O20040315000903 |
News Archive
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.
Immunotec Inc. announced today the enrollment of the first patient in the US Cancer trial of IMN 1207 being run at Beaumont Hospital's Community Clinical Oncology Program (CCOP) in Royal Oak, Michigan. The goal of the study is to determine the effect of IMN 1207, a cysteine-rich whey protein supplement, in preventing additional weight loss in patients with stage IV (advanced) non-small cell lung cancer.
To find the causes for cancer, biochemists and developmental biologists at the University of Innsbruck, Austria, retraced the function of an important human cancer gene 600 million years back in time. For the first time, they have identified the oncogene myc in a fresh water polyp and they have shown that this oncogene has similar biochemical functions in ancestral metazoan and in humans.
There is an ongoing debate about the role of psychological disorder symptoms as risk factors for temporomandibular joint (TMJ) pain. Previous studies have associated depression and TMJ pain but large scale studies have not been performed.
On November 10, 2004 investigators involved in a Phase IIa clinical trial of the novel biotoxin Tetrodotoxin (TTX) for the treatment of opioid withdrawal enrolled their first participants.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Farah Haq, MD 2500 Nesconset Hwy, Stony Brook, NY 11790-2555 Ph: (631) 444-6250 | Dr Farah Haq, MD 4 Smith Haven Mall Ste 202, Lake Grove, NY 11755-1219 Ph: (631) 444-6250 |
News Archive
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.
Immunotec Inc. announced today the enrollment of the first patient in the US Cancer trial of IMN 1207 being run at Beaumont Hospital's Community Clinical Oncology Program (CCOP) in Royal Oak, Michigan. The goal of the study is to determine the effect of IMN 1207, a cysteine-rich whey protein supplement, in preventing additional weight loss in patients with stage IV (advanced) non-small cell lung cancer.
To find the causes for cancer, biochemists and developmental biologists at the University of Innsbruck, Austria, retraced the function of an important human cancer gene 600 million years back in time. For the first time, they have identified the oncogene myc in a fresh water polyp and they have shown that this oncogene has similar biochemical functions in ancestral metazoan and in humans.
There is an ongoing debate about the role of psychological disorder symptoms as risk factors for temporomandibular joint (TMJ) pain. Previous studies have associated depression and TMJ pain but large scale studies have not been performed.
On November 10, 2004 investigators involved in a Phase IIa clinical trial of the novel biotoxin Tetrodotoxin (TTX) for the treatment of opioid withdrawal enrolled their first participants.
› Verified 5 days ago